Wednesday, November 14, 2018 7:27:15 PM
New career post today -
Principal Scientist
Job Description
We are currently seeking a highly motivated individual to join Analytical Development at Momenta Pharmaceuticals. This position will be responsible for overseeing the development and qualifications of binding/ bioassay assays for our advanced programs. The candidate will be involved in all stages of assay development including experimental design and assay optimization with the internal team and Contract Research Organizations (CROs). Hands on experience and proficiency with various bioanalytical and biochemical techniques including, but not limited to, ELISA, MSD, Surface Plasmon Resonance (SPR), flow cytometry and cellular assays are required.
Responsibilities:
Responsible for design, execution, troubleshooting and analysis of experiments
Expertise in SPR, cellular, ELISA and MSD type assays
Mentor and oversight of assay development team, with outstanding communication, analytical and organizational skills
Coordinate project tasks and project timelines
Implement new technologies that can accelerate program timelines.
Author analytical sections for regulatory submissions
Author protocols and reports for analytical characterization and technical transfer
Qualifications:
PhD in biochemistry, biology, chemistry or equivalent discipline and a minimum of 8+ years’ experience or an MS with 10+ years’ experience in a research environment.
Proven experience developing an assay from conception to a qualified/pre-validated state
Hands on experience in one or more types of assays such as SPR, ELISA, MDS, cellular assays and flow cytometry
Expertise in binding kinetics
Highly motivated, flexible, excellent problem solving skills and multi-tasks
Highly collaborative team player who fosters open communication and facilitates mutual understanding and cooperation between all stakeholders
https://osv-momentapharma.wd1.myworkdayjobs.com/en-US/MomentaCareers/job/Cambridge-MA-Bent/Principal-Scientist_REQ-000307
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM